ACTA1 and Hepatic fibrosis: Consistent with the significant reduction of hepatic fibrosis by administration of gemigliptin, hepatic expression of α-SMA, a fibrosis marker, was significantly decreased in the gemigliptin-treated group compared with the MCD-diet fed group (Figure 2F).